Work from multiple laboratories has demonstrated that a “precursor exhausted” or resource population of CTLs in the tumor-draining lymph node that express both the activation marker PD-1 and stemness marker TCF1 are the key responders to checkpoint blockade in preclinical models of melanoma, colorectal carcinoma and chronic viral infection [51–54]. Here, PDCD1 is linked to melanoma.